Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
14 hedge funds and large institutions have $3.06M invested in Evoke Pharma in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
62% more capital invested
Capital invested by funds: $1.89M → $3.06M (+$1.17M)
27% more funds holding
Funds holding: 11 → 14 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$137K |
| 2 |
Renaissance Technologies
New York
|
+$103K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$61.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $891K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $427K | +$15.7K | +20 | +5% |
|
3
Millennium Management
New York
| $411K | – | – | – |
|
|
KCM
4
Knoll Capital Management
Miami,
Florida
| $381K | – | – | – |
|
5
California Public Employees Retirement System
Sacramento,
California
| $251K | – | – | – |
|
|
SOMRS
6
State of Michigan Retirement System
Lansing,
Michigan
| $171K | +$137K | +174 | New |
|
7
Bank of New York Mellon
New York
| $162K | +$2.35K | +3 | +2% |
|
|
8
Renaissance Technologies
New York
| $129K | +$103K | +131 | New |
|
9
Geode Capital Management
Boston,
Massachusetts
| $108K | – | – | – |
|
|
BFA
10
BlackRock Fund Advisors
San Francisco,
California
| $83K | +$61.2K | +78 | +1,300% |
|
11
Bank of America
Charlotte,
North Carolina
| $20K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $16K | +$13.3K | +17 | New |
|
|
BIM
13
BlackRock Investment Management
Wilmington,
Delaware
| $5K | +$1.57K | +2 | +67% |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| $1K | -$4.71K | -6 | -86% |
|
EVOK Hedge Fund Activity: Q2 2016 in Review
14 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2016, worth a combined $3.06M — up 62% from $1.89M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVOK positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was State of Michigan Retirement System, opening a new position worth an estimated $137K. The largest seller was Tower Research Capital (TRC), cutting an estimated $4.71K.
- 14 institutional investors held Evoke Pharma (EVOK) as of Q2 2016, up from 11 in Q1 2016.
- Funds reported $3.06M of Evoke Pharma stock for Q2 2016, up 62% quarter-over-quarter.
- 3 funds opened new Evoke Pharma positions in Q2 2016 and 0 closed out, a net change of +3 holders.
- The largest Evoke Pharma buyer in Q2 2016 was State of Michigan Retirement System, an estimated $137K added.
- The largest Evoke Pharma seller in Q2 2016 was Tower Research Capital (TRC), an estimated $4.71K sold.
Based on aggregated 13F filings for Q2 2016.